Two New Drugs Fight Advanced Melanoma

Wednesday, 29 May 2013 04:56 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
U.S. health regulators approved a pair of drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations. It also approved a diagnostic test to detect the mutations.

The Food and Drug Administration said it approved the drugs, Tafinlar and Mekinist, to be used as single agents and not in combination after the medicines delayed tumor growth in separate clinical trials.
 
After decades with virtually no progress in the fight against advanced melanoma and little to offer patients facing a virtual death sentence, Tafinlar and Mekinist mark the third and fourth new drugs approved by the FDA for metastatic melanoma in the past two years.

Tafinlar, known chemically as dabrafenib, belongs to a class of cancer drugs called as BRAF inhibitors. Mekinist, known chemically as trametinib, inhibits a protein associated with cancerous tumors known as MEK.

Tafinlar was approved to treat patients with melanoma whose tumors express the BRAF V600E gene mutation. Mekinist was approved to treat patients whose tumors express either the BRAF V600E or V600K gene mutations. About half of skin melanomas have a BRAF mutation.

The FDA also approved the THxID BRAF test, made by France's bioMérieux , which will be used to determine if a patient's melanoma cells have the V600E or V600K mutation in the BRAF gene.

Analysts at Cowen and Co forecast sales reaching about $350 million for each drug in 2016.
An estimated 76,690 Americans will be diagnosed with melanoma and 9,480 will die from the disease in 2013, according to the National Cancer Institute.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Immune Drug Fights Skin Cancer

Monday, 22 Dec 2014 16:07 PM

TheU.S. Food and Drug Administration approved Bristol-Myers Squibb's skin cancer drug, more than three months before the . . .

First New Flu Treatment in 15 Years

Monday, 22 Dec 2014 08:19 AM

The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals' intravenous flu drug, sending the company's sha . . .

Drug Fights Antibiotic-Resistant Infection

Saturday, 20 Dec 2014 10:33 AM

Cubist Pharmaceutical drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved